A COMPLETE REVIEW OF MIGRAINE

Balaji O; AMITA D; BAIRY KL

doi:10.22159/ajpcr.2017.v10i10.19207

Authors

Balaji O Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
AMITA D Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
BAIRY KL Professor and chairperson, Department of pharmacology, RAK college of medical sciences, RAK medical and health science university, Ras Al KhaimahUAE.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i10.19207

Keywords:

Headache, Nutraceutical, Prophylaxis, Triptans, Cortical spreading depression

Abstract

Migraine characterized by recurrent headaches present with aura or without aura. Various treatment modalities ranging from 5-hydroxytryptamine 1B/1D agonists, non-steroidal anti-inflammatory drugs to steroids are available for acute treatment of migraine. Prophylaxis for chronic cases is usually with Î² blockers, calcium channel blockers, and antiepileptics. Even many nutraceutical preparations are helpful in migraine including riboflavin, vitamin b12. This review focuses on the newer agents available for treatment of migraine with some sight into their clinical trials.

Downloads

Download data is not yet available.

References

Timothy SY, Mava Y, Bashir HJ, Bwala AY. Impact of weather conditions on migraine in north eastern Nigeria. Int J Pharm Pharm Sci 2011;3(3):133-6.

Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012;380(9859):2163-96.

Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia 2010;30(5):599-609.

Abeer AK, Gihan SL. Flash dissolving sublingual almotriptan malate lyotabs for management of migraine. Int J Pharm Pharm Sci 2017;9(1):125-31.

Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004;24 Suppl 1:9-160.

Lay CL, Broner SW. Migraine in women. Neurol Clin 2009;27(2):503-11.

Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician 2011;83(3):271-80.

Aminoff MJ, Simon RP, Greenberg DA, Michael J. Clinical Neurology. 7th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2009. p. 85-8.

Gasparini CF, Sutherland HG, Griffiths LR. Studies on the pathophysiology and genetic basis of migraine. Curr Genomics 2013;14(5):300-15.

Sarrouilhe D, Dejean C, Mesnil M. Involvement of gap junction channels in the pathophysiology of migraine with aura. Front Physiol 2014;5:78.

Kaiser EA, Russo AF. CGRP and migraine: Could PACAP play a role too? Neuropeptides 2013;47(6):451-61.

Kalra AA, Elliott D. Acute migraine: Current treatment and emerging therapies. Ther Clin Risk Manag 2007;3(3):449-59.

Loder E. Triptan therapy in migraine. N Engl J Med 2010;363(1):63-70.

Lipton RB, Stewart WF, Stone AM, LÃ¡inez MJ, Sawyer JP; Disability in Strategies of Care Study group. Stratified care versus step care strategies for migraine: The disability in strategies of care (DISC) study: A randomized trial. JAMA 2000;284(20):2599-605.

Lipton RB, Stewart WF, Stone AM, LÃ¡inez MJ, Sawyer JP; Disability Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain 2005;115(1-2):1.

Cady RK. Treating an acute attack of migraine. Headache 2008;48(9):1415-6.

Hu XH, Ng-Mak D, Cady R. Does early migraine treatment shorten time to headache peak and reduce its severity? Headache 2008;48(6):914-20.

Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF, et al. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005;45(5):538-45.

Fox AW. Onset of effect of 5-HT1B/1D agonists: A model with pharmacokinetic validation. Headache 2004;44(2):142-7.

Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58.

Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007;47(2):266-9.

Gillman K. Serotonin toxicity. Headache 2008;48(4):640-1.

Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache 2010;50(8):1353-61.

Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46 Suppl 4:S171-81.

Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache 1992;32(1):21-3.

Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010;10:CD008039.

Magis D, Schoenen J. Treatment of migraine: Update on new therapies. Curr Opin Neurol 2011;24(3):203-10.

Tfelt-Hansen P. Triptans versus other drugs for acute migraine. Are there differences in efficacy? A comment. Headache 2008;48(4):601-5.

Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the international migraine pain assessment clinical trial (IMPACT). Cephalalgia 2010;30(11):1336-45.

Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261(8):1174-6.

Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14(1):27-35.

Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010;4:CD008041.

Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med 2002;23(23):141-8.

Gallagher RM. Emergency treatment of intractable migraine. Headache 1986;26(2):74-5.

Saper JR, Silberstein SD, Gordon CD, Hamel RL. Handbook of Headache Management. Baltimore: Williams & Wilkins; 1993. p. 49.

Krymchantowski AV, Barbosa JS. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. Arq Neuropsiquiatr 2001;59:708-11.

Hussain A, Young WB. Steroids and aseptic osteonecrosis (AON) in migraine patients. Headache 2007;47(4):600-4.

Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008;71(22):1821-8.

Loder E. Post-marketing experience with an opioid nasal spray for migraine: Lessons for the future. Cephalalgia 2006;26(2):89-97.

Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: Unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007;28(11):580-7.

FÃ¤rkkilÃ¤ M, Diener HC, GÃ©raud G, LÃ¡inez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11(5):405-13.

Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: A comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005;179(12):207-17.

Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55(6):754-62.

Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol 2006;26(2):188-98.

Bigal ME, Krymchantowski AV, Rapoport AM. Prophylactic migraine therapy: Emerging treatment options. Curr Pain Headache Rep 2004;8(3):178-84.

Kaniecki RG. Migraine prevention with Carvedilol: A prospective, open-label trial. Headache 2003;43:589.

Pietrobon D. Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 2002;25(1):31-50.

Solomon GD. Verapamil in migraine prophylaxis-a five-year review. Headache 1989;29(7):425-7.

Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58(11):1652-9.

Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41 Suppl 1:S3-9.

Freitag FG, Diamond S, Diamond ML. The prophylaxis of migraine with the GABA-agonist, tiagabine: A clinical report. Headache 1999;39:354.

Vaisleb I, Neft R, Schor N. Role of levetiracetam in prophylaxis of migraine headaches in childhood. Neurology 2005;64:A343.

Krusz JC. Zonisamide in the treatment of headache disorders. Cephalalgia 2001;21:374-5.

Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45(2):144-52.

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic

treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ 2001;322(7277):19-22.

Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache J Head Face Pain 1995;35(8):470-1.

Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 2004;55:505-18.

MillÃ¡n-Guerrero RO, Pineda-Lucatero AG, HernÃ¡ndez-BenjamÃn T, Tene CE, Pacheco MF. NÎ±-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and phase II studies. Headache J Head Face Pain 2003;43(4):389-94.

Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: A randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009;8(8):718-23.

Peikert A, Wilimzig C, KÃ¶hne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16(4):257-63.

SÃ¡ndor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64(4):713-5.

Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50(2):466-70.

Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache 2004;44(9):885-90.

Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, Dâ€™Amato CC. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm 2004;69:297-312.

Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;1:CD002286.

Lipton RB, GÃ¶bel H, EinhÃ¤upl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63(12):2240-4.

Giffin NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 2003;23(7):287-92.

Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: A new principle in the treatment of migraine attacks. Cephalalgia 1998;18(1):27-32.

Tfelt-Hansen P. Site of effect of LY2951742 for migraine prophylaxis. Lancet Neurol 2015;14(1):31-2.

Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2015;35(5):379-88.

Meents JE, Neeb L, Reuter U. TRPV1 in migraine pathophysiology. Trends Mol Med 2010;16(4):153-9.

Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME. Role of melatonin in the pathophysiology of migraine: Implications for treatment. CNS Drugs 2006;20(5):343-50.

Magni G, Ceruti S. P2Y purinergic receptors: New targets for analgesic and antimigraine drugs. Biochem Pharmacol 2013;85(4):466-77.